Quantitative Translational Models to Accelerate Hepatitis C Drug Development - Last Chance to Register at Early Bird Rate

Key Highlights: Dr. Wendy Carter from US FDA to share regulatory perspective on DAA trials: Expectations and Current Thinking Dr. Bill Poland and Dr. Jason Chittenden from Pharsight to provide hands on training on HCV modeling and simulation Day 2 of the event will feature hands on training with Phoenix and Trial Simulator software Dr. Lucy Perez from Mckinsey and Co. to share market research on HCV products You might be interested in attending the meeting to know - current state of HCV market - efficient approaches to support decision making for HCV drugs - how modeling and simulation is helping HCV drug development - how to do conduct these analyses Day one of the workshop is designed for drug developers and regulatory experts involved in HCV drug development. Day two is designed for translational research scientists interested in hands-on modeling and simulation training. Please visit the conference website for more information: http://ubsconnect.com/umctm2012.html [cid:[email protected]] Joga Gobburu, PhD, FCP, MBA | Professor | Executive Director Center for Translational Medicine | School of Pharmacy | School of Medicine N407, 20 N Pine, Baltimore, MD-21201 Office: (410) 706-5907 | E-mail: [email protected]<mailto:[email protected]> To receive latest Pharmacometrics news subscribe at http://www.pharmacy.umaryland.edu/ctm/ To unsubscribe, send email to [email protected]<mailto:[email protected]> <<inline: image001.png>>